Literature Analysis of 119 Cases of Adverse Drug Reactions Induced by Infliximab

Abstract

Abstract: Objective To explore the general characteristics of adverse drug reactions induced by infliximab, and provide reference for safe and rational use of infliximab. Methods The articles about infliximab adverse reactions published from 2008 to 2015 in Wanfang and CNKI databases were searched, and the 119 cases documented by the articles were reviewed retrospectively. Results Primary diseases include rheumatoid arthritis, ankylosing spondylitis, ulcerative colonitis, Crohn’s disease, psoriasis, and juvenile idiopathic arthritis. Most adverse reactions occurred during the 3rd and 4th treatments. Infusion reactions were the most common. Skin, respiratory system, digestive system and coronary vascular system were often involved. Prognosis of most adverse reactions were good. Conclusion Adverse drug reactions induced by infliximab involve multiple systems and organs. Vigillance, surveillance and quick management are required.

Key words: infliximab, adverse drug reactions, literature analysis

CLC Number:

R994.11

LI Feng, JIN Hong-zhong. Literature Analysis of 119 Cases of Adverse Drug Reactions Induced by Infliximab[J]. Chinese Journal of Pharmacovigilance, 2016, 13(4): 229-232.

References

[1] 姚新飞,许素清,谢麒麟. 不同输注方法对英夫利西单抗不良反应的影响[J]. 护理学杂志,2013,28(8):17-19.
[2] Fukuyo S, Saito K, Yamaoka K, et al. Efficacy and safety of reducing duration of infliximab infusion[J]. Mod Rheumatol, 2014,24(2):275-280.
[3] 陈国强,郭冬梅,张红卫,等.英夫利西单抗注射安全性的临床观察[J].实用医学杂志,2010,26(13):2415-2416.
[4] Tyler L N, Harville T O, Blackall D P. Multiple alloantibodies after transfusion in an infant treated with infliximab[J]. N Engl J Med,2007,357(20): 2092-2093;
[5] Vultaggio A, Matucci A, Nencini F, et al. Anti-infliximab IgE and non-IgEantibodies and induction of infusion-related severe anaphylactic reactions[J]. Allergy,2010,65(5):657-661.
[6] 杨世春.临床输液反应相关因素探讨及预防[J].中国医药指南,2011,9(20):299-300.
[7] Dixon W G, Hyrich K L, Watson K D, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)[J]. Ann Rheum Dis,2010,69(3):522–528.
[8] Navarra S V, Tang B, Lu L, et al. Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia[J]. Int J Rheum Dis,2014,17(3):291-298.
[9] Solovic I, Sester M, Gomez-Reino J J, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement[J]. Eur Respir J,2010,36(5): 1185-1206.
[10] 中华医学会皮肤性病分会银屑病学组. 中国银屑病治疗专家共识(2014版)[J]. 中华皮肤科杂志,2014,47（3）:213-215.
[11] 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识[J].中华风湿病学杂志,2013,17（8）:508-512.
[12] Bjrnsson E S, Gunnarsson B I, Grndal G, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists[J]. Clin Gastroenterol Hepatol,2015,13(3): 602-608.
[13] Rossi R E, Parisi I, Despott E J, et al. Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management[J]. World J Gastroenterol,2014,20(46):17352-17359.
[14] Esteve M, Saro C, González-Huix F, et al. Chronic hepatitis B
reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis[J]. Gut,2004,53(9):1363–1365.
[15] Castro K R, Aikawa N E, Saad C G, et al. Infliximab induces increase in triglyceride levels in psoriatic arthritis patients[J]. Clin DevImmunol,2011,2011(2):352686.
[16] Koutroubakis I E, Oustamanolakis P, Malliaraki N, et al. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease[J].Eur J Gastroenterol Hepatol,2009,21(3):283–288.
[17] 方霖楷,潘云峰,黄建林,等. 类风湿关节炎伴 HBV 携带患者接受英夫利昔单抗治疗的肝脏安全性观察[J]. 风湿病与关节炎,2014,3（2）:27-29.
[18] Phelan C, Wooltorton E. Infliximab and serious hematologic events[J].CMAJ,2004, 171(9):1045.
[19] 胡扬,王兰,张波,等. 英夫利西单抗诱发再生障碍性贫血[J]药物不良反应杂志,2012,14（6）:382-384.
[20] Mocciaro F, Russo G, Di Mitri R, et al. Infliximab-induced thrombocytopenia in an elderly patient with ileocolonic Crohn’s disease[J]. Inflamm Bowel Dis,2013, 19(4):E52-E53.